Evidence map›Paper›PMID 33363134›Full record

ReviewFrontiers in bioengineering and biotechnology2020

Applications of Nanovaccines for Disease Prevention in Cattle.

Teresia W Maina, Elizabeth A Grego, Paola M Boggiatto, Randy E Sacco, Balaji Narasimhan, Jodi L McGill

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 48 citations in OpenAlex.

  1. Evaluation ofVaccines · 2025
    Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Perspective vaccines for emerging viral diseases in farm animals.Clinical and experimental vaccine research · 2023
    Review
  7. Article
  8. Genotypic and antimicrobial susceptibility ofFrontiers in veterinary science · 2023
    Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. CpG-Based Nanovaccines for Cancer Immunotherapy.International journal of nanomedicine · 2021
    Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Teresia W MainaDepartment of Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, IA, United States.
Elizabeth A GregoDepartment of Chemical and Biological Engineering, Iowa State University, Ames, IA, United States.
Paola M BoggiattoInfectious Bacterial Diseases Research Unit, National Animal Disease Center, Agricultural Research Service, United States Department of Agriculture, Ames, IA, United States.
Randy E SaccoRuminant Diseases and Immunology Research Unit, National Animal Disease Center, Agricultural Research Service, United States Department of Agriculture, Ames, IA, United States.
Balaji NarasimhanDepartment of Chemical and Biological Engineering, Iowa State University, Ames, IA, United States.
Jodi L McGillDepartment of Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, IA, United States.
Iowa State University · USAgricultural Research Service · USNational Animal Disease Center · US

Funding

Development of a mucosal, polyanhydride-based nanoparticle vaccine for use against RSV infection in the neonateR01HD095880 · NICHD · IOWA STATE UNIVERSITY · PI MCGILL, JODI, SACCO, RANDY E · 2019 to 2022
$2.1M
NICHD NIH HHS R01 HD095880
6 · The paper itself

Abstract

Vaccines are one of the most important tools available to prevent and reduce the incidence of infectious diseases in cattle. Despite their availability and widespread use to combat many important pathogens impacting cattle, several of these products demonstrate variable efficacy and safety in the field, require multiple doses, or are unstable under field conditions. Recently, nanoparticle-based vaccine platforms (nanovaccines) have emerged as promising alternatives to more traditional vaccine platforms. In particular, polymer-based nanovaccines provide sustained release of antigen payloads, stabilize such payloads, and induce enhanced antibod- and cell-mediated immune responses, both systemically and locally. To improve vaccine administrative strategies and efficacy, they can be formulated to contain multiple antigenic payloads and have the ability to protect fragile proteins from degradation. Nanovaccines are also stable at room temperature, minimizing the need for cold chain storage. Nanoparticle platforms can be synthesized for targeted delivery through intranasal, aerosol, or oral administration to induce desired mucosal immunity. In recent years, several nanovaccine platforms have emerged, based on biodegradable and biocompatible polymers, liposomes, and virus-like particles. While most nanovaccine candidates have not yet advanced beyond testing in rodent models, a growing number have shown promise for use against cattle infectious diseases. This review will highlight recent advancements in polymeric nanovaccine development and the mechanisms by which nanovaccines may interact with the bovine immune system. We will also discuss the positive implications of nanovaccines use for combating several important viral and bacterial disease syndromes and consider important future directions for nanovaccine development in beef and dairy cattle.

Indexed as

cattleimmune responseinfectious diseasesnanocarriersnanovaccine

Identifiers

PMID33363134
PMCPMC7759628
OpenAlexW3112664691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.